Target prediction of small molecules with information of key molecular interactions

Current Topics in Medicinal Chemistry

Volumn 12, Issue 17, 2012, Pages 1903-1910

  Lin, Jung Hsin ^a,b,c  

^a RESEARCH CENTER FOR APPLIED SCIENCES   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Adverse effect; Drug design; Side effect; Target identification; Target prediction; Toxicity

Indexed keywords

HISTONE DEACETYLASE 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; SIMVASTATIN; ZINC ION;

ARTICLE; BINDING AFFINITY; DATA BASE; DRUG BINDING SITE; DRUG DESIGN; DRUG TARGETING; HUMAN; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR INTERACTION; PHARMACOPHORE; PROTEIN DATA BANK; WEB BROWSER;

BINDING SITES; COMPUTATIONAL BIOLOGY; DATABASES, PROTEIN; DRUG DISCOVERY; LIGANDS; MODELS, MOLECULAR; PROTEOME; SMALL MOLECULE LIBRARIES;

EID: 84872239321     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612804547362     Document Type: Article

References (101)

1. Chan, J.N.Y.; Vuckovic, D.; Sleno, L.; Olsen, J.B.; Pogoutse, O.; Havugimana, P.; Hewel, J.A.; Bajaj, N.; Wang, Y.; Musteata, M.F.; Nislow, C.; Emili, A. Target identification by chromatographic co-elution: monitoring of drug-protein interactions without immobilization or chemical derivatization. Mol. Cell. Proteomics, 2012, 11, M111-016642.
2. Chan, J.N.Y.; Nislow, C.; Emili, A. Recent advances and method development for drug target identification. Trends Pharmacol. Sci., 2010, 31, 82-88.
3. Sharpless, N.E.; DePinho, R.A. Model organisms-The mighty mouse: genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov., 2006, 5, 741-754.
4. Maggi, A.; Ciana, P. Innovation-Reporter mice and drug discovery and development. Nat. Rev. Drug Discov. 2005, 4, 249-255.
5. Stalenhoef, A.F.H.; Mol, M.; Stuyt, P.M.J. Efficacy and tolerability of simvastatin (MK-733). Am. J. Med., 1989, 87, S39-S43.
6. London, S.F.; Gross, K.F.; Ringel, S.P. Cholesterol-lowering agent myopathy (CLAM). Neurology, 1991, 41, 1159-1160.
7. Deslypere, J.P.; Vermeulen, A. Rhabdomyolysis and simvastatin. Ann. Intern. Med., 1991, 114, 342-342.
8. Schalke, B.B.; Schmidt, B.; Toyka, K.; Hartung, H.P. Pravastatinassociated inflammatory myopathy. N. Engl. J. Med., 1992, 327, 649-650.
9. Tobert, J.A. Myolysis and acute renal-failure in a heart-transplant recipient receiving lovastatin-rhabdomyolysis in patients receiving lovastatin after cardiac transplantation-Reply. N. Engl. J. Med., 1988, 318, 48-48.
10. Norman, D.J.; Illingworth, D.R.; Munson, J.; Hosenpud, J. Myolysis and acute renal-failure in a heart-transplant recipient receiving lovastatin. N. Engl. J. Med., 1988, 318, 46-47.
11. East, C.; Alivizatos, P.A.; Grundy, S.M.; Jones, P.H.; Farmer, J.A. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N. Engl. J. Med., 1988, 318, 47-48.
12. Link, E.; Parish, S.; Armitage, J.; Bowman, L.; Heath, S.; Matsuda, F.; Gut, I.; Lathrop, M.; Collins, R.; Grp, S. C. SLCO1B1 variants and statin-induced myopathy-A genomewide study. N. Engl. J. Med., 2008, 359, 789-799.
13. Demierre, M.F.; Higgins, P.D.R.; Gruber, S. B.; Hawk, E.; Lippman, S.M. Statins and cancer prevention. Nat. Rev. Cancer, 2005, 5, 930-942.
14. Lin, Y.C.; Lin, J.H.; Chou, C.W.; Chang, Y.F.; Yeh, S.H.; Chen, C.C. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res., 2008, 68, 2375-2383.
15. Yang, P.M.; Lin, J.H.; Huang, W.Y.; Lin, Y.C.; Yeh, S.H.; Chen, C.C. Inhibition of histone deacetylase activity is a novel function of the antifolate drug methotrexate. Biochem. Biophys. Res. Commun., 2010, 391, 1396-1399.
16. Strebhardt, K.; Ullrich, A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. Cancer, 2008, 8, 473-480.
17. Ehrlich, P. On the present state of chemotherapy. Rep. German Chem. Soc. [Berichte Der Deutschen Chemischen Gesellschaft] 1909, 42, 17-47.
18. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem., 2005, 48, 6523-6543.
19. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today, 2004, 9, 641-651.
20. Huang, N.K.; Chern, Y.; Fang, J.M.; Lin, C.I.; Chen, W.P.; Lin, Y.L. Neuroprotective principles from Gastrodia elata. J. Nat. Prod., 2007, 70, 571-574.
21. Huang, N.K.; Lin, J.H.; Lin, J.T.; Lin, C.I.; Liu, E.M.W.; Lin, C.J.; Chen, W.P.; Shen, Y.C.; Chen, H.M.; Chen, J.B.; Lai, H.L.; Yang, C.W.; Chiang, M.C.; Wu, Y.S.; Chang, C.; Chen, J.F.; Fang, J.M.; Lin, Y.L.; Chern, Y.J. A new drug design targeting the adenosinergic system for Huntington's disease. PLoS ONE, 2011, 6, e20934.
22. Rask-Andersen, M.; Almen, M.S.; Schioth, H.B. Trends in the exploitation of novel drug targets. Nat. Rev. Drug Discov., 2011, 10, 579-590.
23. Russ, A.P.; Lampel, S. The druggable genome: an update. Drug Discov. Today, 2005, 10, 1607-1610.
24. Hopkins, A.L.; Groom, C.R. The druggable genome. Nat. Rev. Drug Discov., 2002, 1, 727-730.
25. Wang, J.C.; Chu, P.Y.; Chen, C.M.; Lin, J.H. idTarget: a web server for identifying proteins targets of small chemical molecules with robust scoring functions and a divide-and-conquer docking approach. Nucleic Acids Res., 2012, 40, W393-W399.
26. Li, H.L.; Gao, Z.T.; Kang, L.; Zhang, H.L.; Yang, K.; Yu, K.Q.; Luo, X.M.; Zhu, W.L.; Chen, K.X.; Shen, J.H.; Wang, X.C.; Jiang, H.L. TarFisDock: a web server for identifying drug targets with docking approach. Nucleic Acids Res., 2006, 34, W219-W224.
27. Yang, L.; Luo, H.; Chen, J.; Xing, Q.H.; He, L. SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemicalprotein interactome. Nucleic Acids Res., 2009, 37, W406-W412.
28. Grinter, S.Z.; Liang, Y.Y.; Huang, S.Y.; Hyder, S.M.; Zou, X.Q. An inverse docking approach for identifying new potential anticancer targets. J. Mol. Graph., 2011, 29, 795-799.
29. Chen, Y.Z.; Ung, C.Y. Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach. J. Mol. Graph., 2001, 20, 199-218.
30. Meslamani, J.; Li, J.B.; Sutter, J.; Stevens, A.; Bertrand, H.O.; Rognan, D. Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand profiling. J. Chem. Inf. Model., 2012, 52, 943-955.
31. Liu, X.F.; Ouyang, S.S.; Yu, B.A.; Liu, Y.B.; Huang, K.; Gong, J.Y.; Zheng, S.Y.; Li, Z.H.; Li, H.L.; Jiang, H.L. PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res., 2010, 38, W609-W614.
32. Wale, N.; Karypis, G. Target fishing for chemical compounds using target-ligand activity data and ranking based methods. J. Chem. Inf. Model., 2009, 49, 2190-2201.
33. van der Horst, E.; Peironcely, J.E.; van Westen, G.J.P.; van den Hoven, O.O.; Galloway, W.; Spring, D.R.; Wegner, J.K.; van Vlijmen, H.W.T.; Ijzerman, A.P.; Overington, J.P.; Bender, A. Chemogenomics approaches for receptor deorphanization and extensions of the chemogenomics concept to phenotypic space. Curr. Top. Med. Chem., 2011, 11, 1964-1977.
34. Koutsoukas, A.; Simms, B.; Kirchmair, J.; Bond, P.J.; Whitmore, A. V.; Zimmer, S.; Young, M. P.; Jenkins, J.L.; Glick, M.; Glen, R.C.; Bender, A. From in silico target prediction to multi-target drug design: Current databases, methods and applications. J. Proteomics, 2011, 74, 2554-2574.
35. Prathipati, P.; Ma, N. L.; Manjunatha, U. H.; Bender, A. Fishing the target of antitubercular compounds: in silico target deconvolution model development and validation. J. Proteome Res., 2009, 8, 2788-2798.
36. Bender, A.; Mikhailov, D.; Glick, M.; Scheiber, J.; Davies, J. W.; Cleaver, S.; Marshall, S.; Tallarico, J. A.; Harrington, E.; Cornella-Taracido, I.; Jenkins, J. L. Use of ligand based models for protein domains to predict novel molecular targets and applications to triage affinity chromatography data. J. Proteome Res., 2009, 8, 2575-2585.
37. Bajorath, J. Computational approaches in chemogenomics and chemical biology: current and future impact on drug discovery. Expert Opin. Drug Discov., 2008, 3, 1371-1376.
38. Bender, A.; Young, D.W.; Jenkins, J.L.; Serrano, M.; Mikhailov, D.; Clemons, P.A.; Davies, J.W. Chemogenomic data analysis: Prediction of small-molecule targets and the advent of biological fingerprints. Comb. Chem. High Throughput Screen., 2007, 10, 719-731.
39. AbdulHameed, M.D.M.; Chaudhury, S.; Singh, N.; Sun, H.; Wallqvist, A.; Tawa, G.J. Exploring polypharmacology using a ROCS-based target fishing approach. J. Chem. Inf. Model., 2012, 52, 492-505.
40. Nidhi; Glick, M.; Davies, J.W.; Jenkins, J.L. Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J. Chem. Inf. Model., 2006, 46, 1124-1133.
41. Jacoby, E. Chemogenomics: Methods and Applications. Humana Press: 2009.
42. Garland, S.L.; Gloriam, D.E. Methods for the successful application of chemogenomics to GPCR drug design. Curr. Top. Med. Chem., 2011, 11, 1870-1871.
43. Laggner, C.; Kokel, D.; Setola, V.; Tolia, A.; Lin, H.; Irwin, J.J.; Keiser, M.J.; Cheung, C.Y.J.; Minor, D.L.; Roth, B.L.; Peterson, R.T.; Shoichet, B.K. Chemical informatics and target identification in a zebrafish phenotypic screen. Nat. Chem. Biol., 2012, 8, 144-146.
44. Fauman, E.B.; Rai, B.K.; Huang, E.S. Structure-based druggability assessment-identifying suitable targets for small molecule therapeutics. Curr. Opin. Chem. Biol., 2011, 15, 463-468.
45. Xie, L.; Bourne, P. E. Structure-based systems biology for analyzing off-target binding. Curr. Opin. Struct. Biol., 2011, 21, 189-199.
46. Ho, C.H.; Piotrowski, J.; Dixon, S.J.; Baryshnikoval, A.; Costanzol, M.; Boone, C. Combining functional genomics and chemical biology to identify targets of bioactive compounds. Curr. Opin. Chem. Biol., 2011, 15, 66-78.
47. Ma, X.H.; Shi, Z.; Tan, C.Y.; Jiang, Y.Y.; Go, M.L.; Low, B.C.; Chen, Y.Z. In-silico approaches to multi-target drug discovery. Pharm. Res., 2010, 27, 739-749.
48. Rognan, D. Structure-based approaches to target fishing and ligand profiling. Mol. Inf. 2010, 29, 176-187.
49. Keiser, M.J.; Irwin, J.J.; Shoichet, B.K. The chemical basis of pharmacology. Biochemistry, 2010, 49, 10267-10276.
50. Kolb, P.; Ferreira, R.S.; Irwin, J.J.; Shoichet, B.K. Docking and chemoinformatic screens for new ligands and targets. Curr. Opin. Biotechnol., 2009, 20, 429-436.
51. Meslamani, J.; Rognan, D. Enhancing the accuracy of chemogenomic models with a three-dimensional binding site kernel. J. Chem. Inf. Model., 2011, 51, 1593-1603.
52. Cheng, T.J.; Li, Q.L.; Wang, Y.L.; Bryant, S.H. Identifying compound-target associations by combining bioactivity profile similarity search and public databases mining. J. Chem. Inf. Model., 2011, 51, 2440-2448.
53. Li, Y.Y.; An, J.H.; Jones, S.J.M. A Computational approach to finding novel targets for existing drugs. PLoS Comput. Biol., 2011, 7.
54. Zhou, X.; Li, Y.Q.; Chen, X. Computational identification of bioactive natural products by structure activity relationship. J. Mol. Graph., 2010, 29, 38-45.
55. Li, L.W.; Bum-Erdene, K.; Baenziger, P.H.; Rosen, J.J.; Hemmert, J.R.; Nellis, J.A.; Pierce, M.E.; Meroueh, S.O. BioDrugScreen: a computational drug design resource for ranking molecules docked to the human proteome. Nucleic Acids Res., 2010, 38, D765-D773.
56. Schalon, C.; Surgand, J.S.; Kellenberger, E.; Rognan, D. A simple and fuzzy method to align and compare druggable ligand-binding sites. Proteins. 2008, 71, 1755-1778.
57. Kellenberger, E.; Foata, N.; Rognan, D. Ranking targets in structure-based virtual screening of three-dimensional protein libraries: Methods and problems. J. Chem. Inf. Model. 2008, 48, 1014-1025.
58. Meslamani, J.; Rognan, D.; Kellenberger, E. sc-PDB: a database for identifying variations and multiplicity of 'druggable' binding sites in proteins. Bioinformatics, 2011, 27, 1324-1326.
59. Kuhn, M.; Szklarczyk, D.; Franceschini, A.; von Mering, C.; Jensen, L. J.; Bork, P. STITCH 3: zooming in on protein-chemical interactions. Nucleic Acids Res., 2012, 40, D876-D880.
60. Gaulton, A.; Bellis, L.J.; Bento, A.P.; Chambers, J.; Davies, M.; Hersey, A.; Light, Y.; McGlinchey, S.; Michalovich, D.; Al-Lazikani, B.; Overington, J.P. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res., 2012, 40, D1100-D1107.
61. Chang, D.T.H.; Ke. C.H.; Lin. J.H.; Chiang. J.H. AutoBind: Automatic extraction of protein-ligand binding affinity data from biological literature. Bioinformatics, 2012, 28, 2162-2168.
62. Ebbels, T.M.D.; Keun, H.C.; Beckonert, O.P.; Bollard, M.E.; Lindon, J.C.; Holmes, E.; Nicholson, J.K. Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: The consortium on metabonomic toxicology screening approach. J. Proteome Res., 2007, 6, 4407-4422.
63. Dearden, J.C. In silico prediction of drug toxicity. J. Comput.-Aided Mol. Des., 2003, 17, 119-127.
64. Greene, N. Computer systems for the prediction of toxicity: an update. Adv. Drug Deliv. Rev., 2002, 54, 417-431.
65. Ridings, J.E.; Barratt, M.D.; Cary, R.; Earnshaw, C.G.; Eggington, C.E.; Ellis, M.K.; Judson, P.N.; Langowski, J.J.; Marchant, C.A.; Payne, M.P.; Watson, W.P.; Yih, T.D. Computer prediction of possible toxic action from chemical structure: An update on the DEREK system. Toxicology, 1996, 106, 267-279.
66. Sushko, I.; Salmina, E.; Potemkin, V.A.; Poda, G.; Tetko, I.V. ToxAlerts: A web server for structural alerts for toxic chemicals and compounds with potential adverse reactions. J. Chem. Inf. Model., 2012, 52, 2310-2316.
67. van Drie, J.H. Monty Kier and the Origin of the Pharmacophore Concept. Int. Electron. J. Mol. Des., 2007, 6, 271-279.
68. Wermuth, G.; Ganellin, C.R.; Lindberg, P.; Mitscher, L.A. Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998). Pure Appl. Chem., 1998, 70, 1129-1143.
69. Southall, N.T.; Dill, K.A.; Haymet, A.D.J. A view of the hydrophobic effect. J. Phys. Chem. B., 2002, 106, 521-533.
70. Langer, T. Pharmacophores in Drug Research. Mol. Inf., 2010, 29, 470-475.
71. Spitzer, G.M.; Heiss, M.; Mangold, M.; Mark, P.; Kirchmair, J.; Wolber, G.; Liedl, K.R. One concept, three implementations of 3d pharmacophore-based virtual screening: distinct coverage of chemical search space. J. Chem. Inf. Model., 2010, 50, 1241-1247.
72. Guner, O.; Clement, O.; Kurogi, Y. Pharmacophore modeling and three dimensional database searching for drug design using catalyst: Recent advances. Curr. Med. Chem., 2004, 11, 2991-3005.
73. Wolber, G.; Langer, T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model., 2005, 45, 160-169.
74. Dixon, S.L.; Smondyrev, A.M.; Knoll, E.H.; Rao, S.N.; Shaw, D.E.; Friesner, R.A. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J. Comput.-Aided Mol. Des., 2006, 20, 647-671.
75. Taminau, J.; Thijs, G.; De Winter, H. Pharao: Pharmacophore alignment and optimization. J. Mol. Graph., 2008, 27, 161-169.
76. Koes, D.R.; Camacho, C.J. Pharmer: efficient and exact pharmacophore search. J. Chem. Inf. Model., 2011, 51, 1307-1314.
77. 2A receptor and adenosine transporter for neuroprotection. Chem. Med. Chem., 2011, 6, 1390-1400.
78. Rogers, D.; Hopfinger, A.J. Application of genetic function approximation to quantitative structure-activity-relationships and quantitative structure-property relationships. J. Chem. Inf. Comput. Sci., 1994, 34, 854-866.
79. Wang, J.C.; Lin, J.H. Scoring functions for protein-ligand interactions. Curr. Pharm. Des., 2013. (PMID: 23016847)
80. Gao, Z.T.; Li, H.L.; Zhang, H.L.; Liu, X.F.; Kang, L.; Luo, X.M.; Zhu, W.L.; Chen, K.X.; Wang, X.C.; Jiang, H.L. PDTD: a webaccessible protein database for drug target identification. BMC Bioinformatics, 2008, 9,104.
81. Zhang, J.X.; Huang, W.J.; Zeng, J.H.; Huang, W.H.; Wang, Y.; Zhao, R.; Han, B.C.; Liu, Q.F.; Chen, Y.Z.; Ji, Z.L. DITOP: druginduced toxicity related protein database. Bioinformatics 2007, 23, 1710-1712.
82. Ji, Z.L.; Han, L.Y.; Yap, C.W.; Sun, L.Z.; Chen, X.; Chen, Y.Z. Drug Adverse Reaction Target Database (DART)-Proteins related to adverse drug reactions. Drug Saf., 2003, 26, 685-690.
83. Chang, D.T.H.; Oyang, Y.J.; Lin, J.H. MEDock: a web server for efficient prediction of ligand binding sites based on a novel optimization algorithm. Nucleic Acids Res., 2005, 33, W233-W238.
84. Chang, D.T.H.; Lin, J.H.; Hsieh, C.H.; Oyang, Y.J. On the design of optimization algorithms for prediction of molecular interactions. Int. J. Artif. Intell. Tools, 2010, 19, 267-280.
85. Wang, J.C.; Lin, J.H.; Chen, C.M.; Perryman, A.L.; Olson, A.J. Robust scoring functions for protein-ligand interactions with quantum chemical charge models. J. Chem. Inf. Model, 2011, 51, 2528-2537.
86. Jakalian, A.; Bush, B.L.; Jack, D.B.; Bayly, C.I. Fast, efficient generation of high-quality atomic Charges. AM1-BCC model: I. Method. J. Comput. Chem., 2000, 21, 132-146.
87. Rousseeuw, P.J.; Van Driessen, K. Computing LTS regression for large data sets. Data Min. Knowl. Discov., 2006, 12, 29-45.
88. Liu, T.Q.; Lin, Y.M.; Wen, X.; Jorissen, R.N.; Gilson, M.K. Binding DB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res., 2007, 35, D198-D201.
89. Hu, L.G.; Benson, M.L.; Smith, R.D.; Lerner, M.G.; Carlson, H.A. Binding MOAD (Mother of All Databases). Proteins, 2005, 60, 333-340.
90. Benson, M.L.; Smith, R.D.; Khazanov, N.A.; Dimcheff, B.; Beaver, J.; Dresslar, P.; Nerothin, J.; Carlson, H.A. Binding MOAD, a high-quality protein-ligand database. Nucleic Acids Res., 2008, 36, D674-D678.
91. Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D.S. DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs. Nucleic Acids Res., 2011, 39, D1035-D1041.
92. Wishart, D.S.; Knox, C.; Guo, A.C.; Shrivastava, S.; Hassanali, M.; Stothard, P.; Chang, Z.; Woolsey, J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res., 2006, 34, D668-D672.
93. Wishart, D.S.; Knox, C.; Guo, A.C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res., 2008, 36, D901-D906.
94. Huang, N.; Shoichet, B.K.; Irwin, J.J. Benchmarking sets for molecular docking. J. Med. Chem., 2006, 49, 6789-6801.
95. Mysinger, M.M.; Carchia, M.; Irwin, J.J.; Shoichet, B.K. Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J. Med. Chem., 2012, 55, 6582-6594.
96. Wang, R.X.; Fang, X.L.; Lu, Y.P.; Yang, C.Y.; Wang, S.M. The PDBbind database: Methodologies and updates. J. Med. Chem., 2005, 48, 4111-4119.
97. Wang, R.X.; Fang, X.L.; Lu, Y.P.; Wang, S.M. The PDBbind database: Collection of binding affinities for protein-ligand complexes with known three-dimensional structures. J. Med. Chem., 2004, 47, 2977-2980.
98. Croft, D.; O'Kelly, G.; Wu, G.M.; Haw, R.; Gillespie, M.; Matthews, L.; Caudy, M.; Garapati, P.; Gopinath, G.; Jassal, B.; Jupe, S.; Kalatskaya, I.; Mahajan, S.; May, B.; Ndegwa, N.; Schmidt, E.; Shamovsky, V.; Yung, C.; Birney, E.; Hermjakob, H.; D'Eustachio, P.; Stein, L. Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res., 2011, 39, D691-D697.
99. Frolkis, A.; Knox, C.; Lim, E.; Jewison, T.; Law, V.; Hau, D.D.; Liu, P.; Gautam, B.; Ly, S.; Guo, A.C.; Xia, J.G.; Liang, Y.J.; Shrivastava, S.; Wishart, D.S. SMPDB: The Small Molecule Pathway Database. Nucleic Acids Res., 2010, 38, D480-D487.
100. Kuhn, M.; Szklarczyk, D.; Franceschini, A.; Campillos, M.; von Mering, C.; Jensen, L. J.; Beyer, A.; Bork, P. STITCH 2: an interaction network database for small molecules and proteins. Nucleic Acids Res., 2010, 38, D552-D556.
101. Kuhn, M.; von Mering, C.; Campillos, M.; Jensen, L.J.; Bork, P. STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res., 2008, 36, D684-D688.